Tag: psychedelics
-
Why the Psychedelic-Assisted Care Field Needs an Association — And Why We Hope It’s Us
If you’re reading this, you already know something the rest of the world is just catching up on: this work is powerful, it’s hard, and it’s lonely in ways that surprise even the most prepared practitioner. You went through training, built a practice or joined a service center, and somewhere along the way realized no…
-
Advocacy Mid-Year Check In
In the first half of 2026, Kathryn Tucker significantly advanced psychedelic medicine advocacy and education, reaching diverse audiences through webinars, podcasts, and in-person events. Her efforts contributed to the historic signing of a Presidential Executive Order on psychedelic policy reform, reflecting her influential role in shaping legal and public perspectives on the subject.
-
FDA – Public Comments
Dear NPA Community, This is a pivotal moment. The FDA has announced a public hearing on the future of psychedelic therapy, and they are actively seeking input from patients, practitioners, advocates, and the broader community. On September 14, 2026, the FDA will hold its Considerations for Potential Future Therapeutic Use of Psychedelic Drugs Public Hearing.…
-
From Cannabis to Psilocybin: What Schedule III Rescheduling for Cannabis Tells Us About the Road Ahead
The federal rescheduling of medical cannabis from Schedule I to Schedule III is the most consequential shift in U.S. controlled substance policy in over fifty years. For those building the infrastructure for legal psilocybin medicine, it is also the clearest map yet of where this field is headed. The banking barriers, insurance gaps, and tax…
-
The Executive Order on Psychedelic Medicine Is a Signal, Not a Solution. Here’s What Comes Next.
In April 2026, President Trump signed an executive order accelerating research and access to psychedelic therapies. For patients, advocates, and practitioners, it is the clearest federal signal yet that the landscape is shifting. But a signal is not a solution. Here is what the order actually does, what it leaves unresolved, and why the window…
-
New Mexico Funds Psilocybin Therapy for Low-Income Patients. A Breakthrough for Access.
New Mexico has taken a major step forward in their impending plan to allow for psychedelic-assisted therapy. $630,000 in state funding has been allocated to expand access for low-income patients. The investment, directed to the Psilocybin Treatment Equity Fund, positions the state at the forefront of equitable mental health innovation in the United States. A…